Oramed Pharmaceuticals Inc.
Company Snapshot: Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD™) technology is based on over 30 years of research by top scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).
- Nov 13 2018 Oramed Completes Over 50% Randomization in Its Pivotal 90-Day Clinical Study
- Nov 5 2018 Oramed to Present at the Tides Europe 2018 Conference
- Oct 23 2018 Oramed to Present at Cardiometabolic Health Congress
- Oct 4 2018 Oramed Enrolls First Patient in Its Clinical Study for Oral Insulin in the Treatment of NASH
- Sep 17 2018 Oramed Receives FDA Clearance for IND Application for Its Oral GLP-1 Analog Capsule